AVORO CAPITAL ADVISORS LLC
Adviser information for AVORO CAPITAL ADVISORS LLC last updated from Form ADV on March 5th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.
Advisory Business
Type of Organization | Limited Liability Company |
---|---|
Fiscal Year End | DECEMBER |
Legal Location | Delaware, United States |
Employees
Total Number of Employees | 15 |
---|---|
Investment Advisory/Research | 10 |
Registered Broker-Dealer Representatives | 0 |
Registered State Investment Advisers | 0 |
Licensed Agents of an Insurance Company | 0 |
No. of Firms/People that Solicit Clients | 0 |
RAUM
Provides Management of Securities Portfolios | Yes |
---|
Type | Accounts | RAUM |
---|---|---|
Discretionary | 3 | $8.7B |
Non-Discretionary | 0 | $0 |
Total | 3 | $8.7B |
Clients
Type | Number | RAUM |
---|---|---|
Individuals | 0 | $0 |
HNW Individuals | 0 | $0 |
Banking or thrift institutions | 0 | $0 |
Investment companies | 0 | $0 |
Business development companies | 0 | $0 |
Pooled investment vehicles | 3 | $8.7B |
Pension and profit sharing plans | 0 | $0 |
Charitable organizations | 0 | $0 |
State or municipal gov entities | 0 | $0 |
Other investment advisers | 0 | $0 |
Insurance companies | 0 | $0 |
Sovereign wealth funds and foreign official institutions | 0 | $0 |
Corporations or other businesses | 0 | $0 |
Other | 0 | $0 |
Type | Number |
---|---|
No. of Non-RAUM Clients | 0 |
No. of Non-U.S. Clients | 33 |
Services
Advisory Services | Portfolio management for pooled investment vehicles |
---|---|
Compensation | % of AUMPerformance-based fees |
Other Business Activities | Commodity pool operator or commodity trading advisor |
Principal Office
110 GREENE STREETSUITE 800
NEW YORK
NY
United States
Monday - Friday, 8AM - 6PM
Tel: 212-937-4970, Fax: 646-757-2710
Websites
Chief Compliance Officer
SCOTT EPSTEIN
CHIEF COMPLIANCE OFFICER
110 GREENE STREET
SUITE 800
NEW YORK
NY
United States
Tel:
212-937-4975
Fax:
646-757-2710
S*******@***************M
(Full email address available in API data)
Industry Affiliates
AVORO VENTURES GP LLC | Sponsor, GP, manager of pooled investment vehicles |
Private Funds
Name | Type | Assets $USD | Min Investment $USD | No. Owners |
---|---|---|---|---|
AVORO LIFE SCIENCES FUND LLC | Hedge Fund | $8,572.1M | $1.0M | 405 |
AVORO VENTURES FUND L.P. | Venture Capital Fund | $165.8M | $5.0M | 48 |
Control Persons
Name | Type | Entity | Title | Since | Ownership |
---|---|---|---|---|---|
AGHAZADEH, BEHZAD | Individual | – | MANAGING DIRECTOR | 09/2017 | < 5% |
EPSTEIN, SCOTT, ANDREW | Individual | – | CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER | 06/2014 | < 5% |
AVORO CAPITAL L.P. | Domestic Entity | – | DIRECT OWNER | 05/2019 | > 75% |
AGHAZADEH, BEHZAD | Individual | AVORO CAPITAL L.P. | LIMITED PARTNER | 05/2019 | 50-75% |
AGHAZADEH, BEHZAD | Individual | AVORO CAPITAL GP LLC | MEMBER | 05/2019 | 50-75% |
AVORO CAPITAL GP LLC | Domestic Entity | AVORO CAPITAL L.P. | GENERAL PARTNER | 05/2019 | |
KONG, GARHENG, ALBERT | Individual | AVORO CAPITAL GP LLC | MEMBER | 05/2019 | 50-75% |
No. Employees, Historic
RAUM, Historic
No. Clients, Historic
Holdings
From latest 13F, filed August 14th, 2024 for period ending June 30th, 2024
Name | Class | Value $USD | # Shares | Private Fund |
---|---|---|---|---|
AADI BIOSCIENCES INC | Common | 4M | 3M | – |
ADVERUM BIOTECHNOLOGIES INC | Common | 3M | 417K | – |
ALNYLAM PHARMCEUTICALS INC. | Common | 97M | 400K | – |
AMICUS THERAPEUTICS INC. | Common | 272M | 27M | – |
APELLIS PHARMACEUTICALS INC. | Common | 426M | 11M | – |
ARGENX SE | Sponsored ADR | 533M | 1M | – |
ARROWHEAD PHARMACEUTICALS INC. | Common | 231M | 9M | – |
ASCENDIS PHARMA | Sponsored ADR | 572M | 4M | – |
AUTOLUS THERAPEUTICS PLC | Sponsored ADR | 43M | 12M | – |
AVIDITY BIOSCIENCES INC | Common | 266M | 7M | – |
BICYCLE THERAPEUTICS PLC | Sponsored ADR | 14M | 700K | – |
BIOCRYST PHARMACEUTICALS INC | Common | 78M | 13M | – |
BIOMARIN PHARMACEUTICAL INC | Common | 375M | 5M | – |
CEREVEL THERAPEUTICS HLDNG | Common | 308M | 8M | – |
CG ONCOLOGY INC | Common | 22M | 700K | – |
DYNE THERAPEUTICS INC. | Common | 4M | 116K | – |
INTRA-CELLULAR THERAPIES INC | Common | 205M | 3M | – |
IOVANCE BIOTHERAPEUTICS INC | Common | 94M | 12M | – |
KRYSTAL BIOTECH INC | Common | 447M | 2M | – |
KURA ONCOLOGY INC | Common | 73M | 4M | – |
KYMERA THERAPEUTICS INC | Common | 116M | 4M | – |
MADRIGAL PHARMACEUTICALS INC | Common | 576M | 2M | – |
MANNKIND CORP | Common | 46M | 9M | – |
MERUS N V | Common | 80M | 1M | – |
MONTE ROSA THERAPEUTICS INC | Common | 17M | 5M | – |
MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 122M | 3M | – |
NEUROGENE INC | Common | 802K | 22K | – |
OCULAR THERAPEUTIX INC | Common | 55M | 8M | – |
SAREPTA THERAPEUTICS INC | Common | 474M | 3M | – |
SOLENO THERAPEUTICS INC | Common | 85M | 2M | – |
SPDR SERIES TRUST - S&P BIOTECH | ETF | 281M | 3M | – |
SPYRE THERAPEUTICS INC | Common | 43M | 2M | – |
SYNDAX PHARMACEUTICALS INC | Common | 80M | 4M | – |
TAYSHA GENE THERAPIES INC | Common | 42M | 19M | – |
TOURMALINE BIO INC | Common | 29M | 2M | – |
ULTRAGENYX PHARMACEUTICAL INC | Common | 34M | 830K | – |
UNITED THERAPEUTICS CORP | Common | 911M | 3M | – |
VAXCYTE INC | Common | 43M | 575K | – |
VERA THERAPEUTICS INC | Common | 156M | 4M | – |
VERRICA PHARMACEUTICALS INC | Common | 29M | 4M | – |
XENON PHARMACEUTICALS INC | Common | 221M | 6M | – |